https://www.fiercebiotech.com/biotech/nuvalent-nets-50m-to-create-better-targeted-meds-for-cancer-resistance
Nuvalent nets $50M to create better targeted meds for cancer resistance | Fierce Biotech
Jan 27, 2021 - Targeted therapies have changed the game for cancer patients with tumor-driving mutations like ALK or ROS.
https://www.prnewswire.com/news-releases/nuvalent-presents-preliminary-data-for-neladalkib-in-advanced-alk-positive-solid-tumors-beyond-nsclc-at-esmo-2025-302588111.html
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
https://nuvalent.com/
Nuvalent | Precisely targeted therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
targeted therapiesfor patientspreciselycancer
https://job-boards.greenhouse.io/nuvalent/jobs/5842035004?gh_jid=5842035004
Job Application for Senior Manager, Formulation Sciences at Nuvalent, Inc.
Cambridge, MA / Remote
job applicationfor seniormanagerformulationsciences
https://aijourn.com/nuvalent-to-present-pivotal-data-from-arros-1-clinical-trial-of-zidesamtinib-for-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-at-wclc-2025-presidential-symposium/
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated...
Aug 13, 2025 - CAMBRIDGE, Mass., Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on